The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech company, stressed that point with TheStreet Pro’s Chris ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

From my colleague Elaine Chen: Wave Life Sciences said today that interim data show its investigational siRNA therapy cut ...

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

Sartorius Group is expected to continue delivering high-single digit CER sales growth in 2026, supported by strong consumables performance. JPMorgan maintains an Overweight rating with price targets ...